Analysts Offer Insights on Healthcare Companies: Kala Pharmaceuticals (KALA) and Milestone Pharmaceuticals (MIST)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kala Pharmaceuticals (KALA – Research Report) and Milestone Pharmaceuticals (MIST – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kala Pharmaceuticals (KALA)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Kala Pharmaceuticals, with a price target of $30.00. The company’s shares closed last Friday at $18.62.
According to TipRanks.com, Suvannavejh is a 4-star analyst with an average return of
Kala Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.40, a 20.0% upside from current levels. In a report issued on September 3, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $23.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Milestone Pharmaceuticals (MIST)
In a report released today, Ritu Baral from TD Cowen maintained a Hold rating on Milestone Pharmaceuticals. The company’s shares closed last Friday at $1.96.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Milestone Pharmaceuticals with a $4.33 average price target.
Read More on KALA:
Disclaimer & DisclosureReport an Issue
- Kala Pharmaceuticals price target raised to $33 from $15 at Oppenheimer
- Kala Pharmaceuticals initiated with an Outperform at Mizuho
- Kala Pharmaceuticals management to meet with Piper Sandler
- Kala Pharmaceuticals initiated with an Outperform at LifeSci Capital
- Kala Pharmaceuticals Appoints Todd Bazemore as CEO
